PulseSight Therapeutics is at the forefront of developing innovative non-viral vectorized therapies specifically targeting severe retinal diseases, particularly age-related macular degeneration (AMD). Their approach utilizes a proprietary electro-transfection delivery device to administer plasmid-vectorized therapeutic proteins directly to the retina. This method aims to provide longer-lasting and more effective treatment options compared to existing therapies, addressing the complex pathophysiological mechanisms involved in AMD. The company is advancing two key programs: PST-611, targeting geographic atrophy in late-stage dry AMD, and PST-809, aimed at wet AMD. Both programs are nearing clinical phase, building on extensive preclinical studies that demonstrate their potential efficacy and safety.

PST-611 focuses on delivering a plasmid that expresses human transferrin, which helps regulate iron levels in the eye, thereby reducing oxidative stress and preventing retinal degeneration. In contrast, PST-809 combines two therapeutic proteins to target both vascular endothelial growth factor (VEGF) and VEGF-independent pathways, potentially improving treatment compliance by reducing the frequency of required injections. This dual-action approach not only addresses immediate symptoms but also aims to promote long-term retinal health. PulseSight's commitment to addressing the unmet needs in AMD treatment is supported by a robust intellectual property portfolio and a team of experienced professionals in ophthalmology and gene therapy.

France

PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.


PulseSight Therapeutics

Company Details